Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Life expectancy of at least 12 weeks
Histologically confirmed B-cell non-Hodgkin's lymphoma that has relapsed after or failed to respond to at least one prior treatment regimen and for which no suitable therapy of curative intent or higher priority exists
A clinical indication for treatment as determined by the investigator
Availability of archival or freshly collected tumor tissue before study enrollment
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Fasting (greater than or equal to \[\>=\] 8 hours) glucose less than or equal to (\<=) 160 milligrams per deciliter (mg/dL)
Participants requiring anti-diabetic medications must be on a stable dose and regimen for \>=4 weeks
Adequate hematologic function without growth factor or transfusion support
For women who are not postmenopausal (\>= 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods as specified in protocol
For men: agreement to remain abstinent or use a condom plus an additional contraceptive method as specified in protocol
You may not be if
Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1
Treatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
Prior allogeneic stem cell transplant
Current or history of CNS lymphoma
Current Grade greater than (\>) 1 toxicity (except alopecia and anorexia) from prior therapy
Current Grade \>1 peripheral neuropathy from any cause
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Prior irradiation to lung fields
Clinically significant pulmonary disease
Recent major surgery within 4 weeks prior to Cycle 1, Day 1, other than superficial lymph node biopsies for diagnosis
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Presence of positive test results for hepatitis B (hepatitis B surface antigen \[HbsAg\] and/or total hepatitis B core antibody \[anti-HBc\]) or hepatitis C (hepatitis C virus \[HCV\] antibody)
Known history of human immunodeficiency virus (HIV) seropositive status
Women who are pregnant or lactating or intending to become pregnant during the study
Any abnormal laboratory values as specified in protocol
Requirement for any excluded medication as specified in protocol
History of other malignancy that could affect compliance with the protocol or interpretation of results
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications, including inadequately controlled diabetes or significant cardiovascular disease
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
Participants in Phase 1b Stage Only: Vaccination with live vaccines within 6 months before Cycle 1, Day 1
